Back to Search Start Over

PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression.

Authors :
Seminario, Maria-Cristina
Precht, Patricia
Wersto, Robert P
Gorospe, Myriam
Wange, Ronald L
Source :
Oncogene; 11/6/2003, Vol. 22 Issue 50, p8195-8204, 10p
Publication Year :
2003

Abstract

The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27<superscript>KIP1</superscript> expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.Oncogene (2003) 22, 8195-8204. doi:10.1038/sj.onc.1206872 [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09509232
Volume :
22
Issue :
50
Database :
Complementary Index
Journal :
Oncogene
Publication Type :
Academic Journal
Accession number :
11309193
Full Text :
https://doi.org/10.1038/sj.onc.1206872